InVitae Corp (NYSE:NVTA) – Svb Leerink issued their Q1 2021 earnings estimates for InVitae in a research note issued to investors on Tuesday, August 6th, Zacks Investment Research reports. Svb Leerink analyst P. Souda anticipates that the medical research company will post earnings of ($0.26) per share for the quarter. Svb Leerink also issued estimates for InVitae’s Q2 2021 earnings at ($0.25) EPS.
Several other equities analysts have also weighed in on NVTA. Benchmark reaffirmed a “buy” rating and set a $28.00 price objective (up previously from $26.00) on shares of InVitae in a research report on Wednesday, August 7th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of InVitae in a research report on Tuesday, June 11th. Leerink Swann set a $31.00 price objective on shares of InVitae and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Oppenheimer set a $34.00 price objective on shares of InVitae and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $28.17.
Shares of NVTA opened at $24.00 on Thursday. The firm has a market cap of $2.52 billion, a PE ratio of -12.37 and a beta of 2.53. The firm’s 50 day moving average price is $24.86 and its 200 day moving average price is $21.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 7.18 and a current ratio of 7.18. InVitae has a twelve month low of $9.04 and a twelve month high of $28.75.
InVitae (NYSE:NVTA) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.06). The business had revenue of $53.48 million for the quarter, compared to the consensus estimate of $50.17 million. InVitae had a negative net margin of 83.69% and a negative return on equity of 58.48%. InVitae’s revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.47) EPS.
In other news, General Counsel Thomas Brida sold 13,663 shares of InVitae stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $25.29, for a total value of $345,537.27. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Shelly D. Guyer sold 24,447 shares of InVitae stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $25.38, for a total transaction of $620,464.86. The disclosure for this sale can be found here. In the last three months, insiders sold 137,547 shares of company stock worth $3,215,811. Insiders own 5.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Parallel Advisors LLC acquired a new stake in shares of InVitae in the second quarter worth $25,000. PNC Financial Services Group Inc. acquired a new stake in shares of InVitae in the 1st quarter valued at $26,000. Certified Advisory Corp acquired a new stake in shares of InVitae in the 1st quarter valued at $30,000. First Quadrant L P CA acquired a new stake in shares of InVitae in the 2nd quarter valued at $36,000. Finally, Signaturefd LLC acquired a new stake in shares of InVitae in the 1st quarter valued at $47,000. Institutional investors and hedge funds own 87.51% of the company’s stock.
InVitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.